Table 2.
Prostate Cancer Patient Clinical Characteristics
| Characteristic | Total | Brooklyn | Guyana | Trinidad &Tobago | P-Value |
|---|---|---|---|---|---|
| N = 6,142 N (%) |
N = 1,100 N (%) |
N = 609 N (%) |
N = 4,433 1N (%) |
||
| Stage | < 0.0001 | ||||
| I-III | 3,236 (52.7) | 996 (90.5) | 248 (40.8) | 1,992 (44.9) | |
| IV | 661 (10.8) | 65 (5.91) | 13 (2.10) | 583 (13.2) | |
| Unstaged | 2,245 (36.5) | 39 (3.59) | 348 (57.1) | 1,858 (41.9) | |
| Grade | <0.0001 | ||||
| Well | 602 (12.1) | - | 10 (1.64) | 592 (13.5) | |
| Moderate | 740 (14.8) | - | 8 (1.31) | 732 (16.7) | |
| Poor | 400 (8.01) | - | 6 (0.99) | 394 (8.98) | |
| Undifferentiated | 17 (0.39) | - | - | 17 (0.39) | |
| Unknown | 3,237 (64.7) | - | 585 (96.06) | 2,652 (60.45) | |
| Histology | 0.000 | ||||
| Glandular intraepithelial neoplasia, grade III | 3 (0.05) | 2 (0.18) | - | 1 (0.02) | |
| Carcinoma, NOS | 1,697 (27.63) | 17 (1.55) | 579 (95.1) | 1,101 (24.8) | |
| Adenocarcinoma | 4,245 (69.11) | 1,078 (98.0) | 30 (4.90) | 3,137 (70.8) | |
| Other1 | 197 (3.21) | 3 (0.27) | - | 194 (4.38) | |
| Status | < 0.0001 | ||||
| Alive | 2,878 (46.9) | 897 (81.5) | 173 (28.4) | 1,808 (40.7) | |
| Dead | 3,253 (52.9) | 203 (18.5) | 435 (71.4) | 2,615 (59.0) | |
| Unknown | 11 (0.20) | - | 1 (0.20) | 10 (0.30) | |
| Median Follow-up, months (range) | 18 months (1 – 305) | 42 months(1–150) | 5 months (1–82) | 14 months (1–305) |
NOS, not otherwise specified
1
Other (histology): Tumorlet, NOS; Small cell carcinoma; Squamous cell carcinoma; Transitional cell carcinoma; Cribriform carcinoma; Signet ring cell carcinoma; Infiltrating duct carcinoma; Infiltrating duct mixed with other carcinoma; Acinar cell carcinoma; Adenosquamous carcinoma; Sarcoma.